Literature DB >> 7023761

Prognostic significance of immunological tests in lung cancer.

I J Check, R L Hunter, T Karrison, T R DeMeester, H M Golomb, J Vardiman.   

Abstract

We performed a battery of tests on peripheral blood samples from 94 patients with lung cancer to determine the extent to which immunological depression was due to abnormal lymphocyte function, as compared to changes in the number of lymphoid cells in the peripheral blood or in the efficiency of purification of cells in Ficoll-Hypaque gradients in preparation for testing. The percentage of lymphocytes in the gradient-derived cell suspension (%LG) was the most informative test. It decreased significantly with advancing stage of cancer and could predict survival of patients with uniform stage. The %LG correlated with survival better than any other test when multivariate analyses of all test combinations were performed. Low values of %LG reflected both the depressed lymphocyte counts and the altered buoyant density of the leucocytes of many patients with advanced cancer. A large proportion of the depression in other immune function tests was statistically attributed to changes in %LG. We concluded that this simple measurement provides valuable information about patients with lung cancer.

Entities:  

Mesh:

Year:  1981        PMID: 7023761      PMCID: PMC1537274     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

1.  SRBC rosette formation as a human T lymphocyte marker.

Authors:  M Jondal
Journal:  Scand J Immunol       Date:  1976-06       Impact factor: 3.487

2.  Immunologic testing as a guide to cancer management.

Authors:  H J Wanebo
Journal:  Surg Clin North Am       Date:  1979-04       Impact factor: 2.741

3.  Plasma cortisol levels in lung cancer.

Authors:  I Lichter; N E Sirett
Journal:  Br Med J       Date:  1968-04-20

4.  Five-year cancer cure: relation to total amount of peripheral lymphocytes and neutrophils.

Authors:  A Riesco
Journal:  Cancer       Date:  1970-01       Impact factor: 6.860

5.  The relationship between immune reactivity, serum cortisol, and stage of disease in patients with non-oat-cell bronchogenic carcinoma.

Authors:  T R DeMeester; H M Golomb; P Dudek; R L Hunter; V S Fang
Journal:  Surgery       Date:  1979-07       Impact factor: 3.982

6.  Discordance among cell-mediated cytolytic mechanisms in cancer patients: importance of the assay system.

Authors:  W J Catalona; T L Ratliff; R E McCool
Journal:  J Immunol       Date:  1979-03       Impact factor: 5.422

7.  Cytotaxins after the sedimentation behavior of human granulocytes.

Authors:  N Catsimpoolas; S R Kurtz; E M Skrabut; A L Griffith; C R Valeri
Journal:  Science       Date:  1979-08-31       Impact factor: 47.728

8.  Cancer-specific density changes in lymphocytes after stimulation with phytohaemagglutinin.

Authors:  J A Pritchard; W H Sutherland; J E Seaman; T J Deeley; I H Evans; I J Kerby; K W James; I C Paterson
Journal:  Lancet       Date:  1978-12-16       Impact factor: 79.321

9.  Contamination of mononuclear cell suspensions obtained from cancer patients by the Böyum method.

Authors:  G A Currie; D W Hedley; R E Nyholm; S A Taylor
Journal:  Br J Cancer       Date:  1978-10       Impact factor: 7.640

10.  Restricted autologous lymphocytotoxicity in lung neoplasia.

Authors:  B M Vose; F Vánky; M Fopp; E Klein
Journal:  Br J Cancer       Date:  1978-09       Impact factor: 7.640

View more
  1 in total

1.  A monocyte function test (complement receptor enhancement) to assess the extent of bronchial carcinoma.

Authors:  M Carroll; M J Smith; M E Hodson; A B Kay
Journal:  Thorax       Date:  1987-01       Impact factor: 9.139

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.